Pradžia › Kartotinė mieloma › Džordžija › Atlanta
Kartotinė mieloma klinikiniai tyrimai Atlanta, GA
Vienas tyrimas dėl Kartotinė mieloma ieško dalyvių vietoje Atlanta arba jos apylinkėse. Atidarykite jį, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Renkami dalyviai3 fazė
- Research Site, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Renkami dalyviai1/2 fazė
- Emory University Winship Cancer Center, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai3 fazė
- Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Renkami dalyviai1 fazė
- Research Site, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Renkami dalyviai1 fazė
- Winship Cancer Institute Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai3 fazė
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- Emory University Winship Cancer Institute, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Renkami dalyviai3 fazė
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Renkami dalyviai4 fazė
- Emory University, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1/2 fazė
- Emory University Hospital, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Renkami dalyviai2/3 fazė
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Renkami dalyviai2 fazė
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Renkami dalyviai1/2 fazė
- Winship Cancer Institute of Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
Renkami dalyviaiStebimasis tyrimas
- Emory University, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Renkami dalyviai3 fazė
- Winship Cancer Institute, Emory University, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Renkami dalyviai3 fazė
- Emory University Hospital Midtown, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Renkami dalyviai2 fazė
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Emory University Hospital, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1/2 fazė
- Research Site, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Renkami dalyviai1/2 fazė
- Research Site, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- The Winship Cancer Institute of Emory University, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Renkami dalyviai1/2 fazė
- Research Site, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Renkami dalyviai3 fazė
- Research Site, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Renkami dalyviai1 fazė
- Winship Cancer Institute, Emory University, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Renkami dalyviai2 fazė
- Winship Cancer Institute, Emory University, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Renkami dalyviai4 fazė
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Renkami dalyviai1/2 fazė
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Northside Hospital, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Renkami dalyviai1 fazė
- Winship Cancer Institute of Emory University, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Renkami dalyviai1/2 fazė
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
Renkami dalyviai1 fazė
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Renkami dalyviai
- Emory University Hospital/Winship Cancer Institute, Atlanta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Renkami dalyviai3 fazė
- Emory University Hospital, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Renkami dalyviai1 fazė
- Emory Winchip Cancer Center, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Renkami dalyviai3 fazė
- GSK Investigational Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
Renkami dalyviai2 fazė
- Caitlin Guzowski, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Renkami dalyviai1/2 fazė
- Emory University Hospital, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Renkami dalyviai1 fazė
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Renkami dalyviai1/2 fazė
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Renkami dalyviai1 fazė
- Northside Hospital, Atlanta
Kartotinė mieloma tyrimai kituose miestuose
- New York City, NY60 tyrimai
- Boston, MA42 tyrimai
- Houston, TX38 tyrimai
- Durham, NC37 tyrimai
- Nashville, TN32 tyrimai
- Denver, CO27 tyrimai
- Rochester, MN24 tyrimai
- St. Louis, MO24 tyrimai
- Columbus, OH24 tyrimai
- Baldwin Park, CA23 tyrimai
- Chicago, IL22 tyrimai
- Seattle, WA22 tyrimai
Kiti tyrimai Atlanta
- Vėžys (visų tipų)49 tyrimai
- Nedidelinių ląstelių plaučių vėžys47 tyrimai
- Krūties vėžys41 tyrimas
- Prostatos vėžys33 tyrimai
- Ūmi mieloidinė leukemija30 tyrimai
- Kiaušidžių vėžys29 tyrimai
- Plaučių vėžys29 tyrimai
- Storosios ir tiesiosios žarnos vėžys29 tyrimai
- Metastatinis vėžys28 tyrimai
- Širdies nepakankamumas25 tyrimai
- Didelis depresinis sutrikimas25 tyrimai
- Galvos ir kaklo plokščiųjų ląstelių karcinoma24 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.